Nathalie Kingston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nathalie Kingston has a total of 321 co-authors. Here are the top co-authors by number of shared publications:
- Gerome Breen
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
9 shared publications - John Richard Bradley
NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge, UK
9 shared publications - Jonathan Richard Iain Coleman
King's College London
8 shared publications - Matthew Hotopf
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
8 shared publications - Thalia Catherine Eley
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
8 shared publications - Sang Hyuck Lee
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
7 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (11) , 6224-6237
Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one independent genome-wide significant locus and three gene-level associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four genome-wide significant loci and three gene-level associations were identified for GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
- 29 June 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (11) , 6224-6237
Open AccessGenome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one independent genome-wide significant locus and three gene-level associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four genome-wide significant loci and three gene-level associations were identified for GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
- Open Access
- 2 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Genetic landscape of adult executive function reveals a cell-type-specific developmental origin
Executive function is an essential cognitive domain for typical human behavior which is disrupted in neurodevelopmental and neurodegenerative disorders, but little is known about its underlying molecular basis. To address this, we perform genome-wide association studies (GWAS) using three different measures of executive function in UK Biobank ( N = 84,238) and NIHR BioResource’s Genes and Cognition ( N = 9932) study participants, followed by a meta-analysis. The trail-making alphanumeric (TMA) measure is the most heritable phenotype (h²=7-26%), associated with 18 independent loci that exhibit a similar direction of effect in both cohorts. Across these loci, in-silico follow-up implicates 178 genes, of which NT5DC2 and RP11-579E24.2 are independently replicated prior to meta-analysis. TMA is linked to pan-cerebral differences in brain structure, with brain-enriched genes showing a biphasic expression profile from early development through to later life. Our data implicate specific cell types, histone modifications and butyrophilin immunoglobulin family proteins as potential targets for promoting cognitive resilience.
- 2 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessGenetic landscape of adult executive function reveals a cell-type-specific developmental origin
Executive function is an essential cognitive domain for typical human behavior which is disrupted in neurodevelopmental and neurodegenerative disorders, but little is known about its underlying molecular basis. To address this, we perform genome-wide association studies (GWAS) using three different measures of executive function in UK Biobank ( N = 84,238) and NIHR BioResource’s Genes and Cognition ( N = 9932) study participants, followed by a meta-analysis. The trail-making alphanumeric (TMA) measure is the most heritable phenotype (h²=7-26%), associated with 18 independent loci that exhibit a similar direction of effect in both cohorts. Across these loci, in-silico follow-up implicates 178 genes, of which NT5DC2 and RP11-579E24.2 are independently replicated prior to meta-analysis. TMA is linked to pan-cerebral differences in brain structure, with brain-enriched genes showing a biphasic expression profile from early development through to later life. Our data implicate specific cell types, histone modifications and butyrophilin immunoglobulin family proteins as potential targets for promoting cognitive resilience.
- Open Access
Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one SNP-based independent locus and three gene-level genome-wide significant (GWS) associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four GWS SNP-based loci and three gene-level loci were associated with GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
Open AccessGenome-wide genetic overlap between fear-based disorders and generalised anxiety disorder
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one SNP-based independent locus and three gene-level genome-wide significant (GWS) associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four GWS SNP-based loci and three gene-level loci were associated with GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
- Open Access
Disentangling Perinatal Depression from General Major Depression: A GWAS Meta-Analysis and Genetic Correlation Approach in European Datasets
Perinatal depression (PND), defined as depression occurring during the perinatal period, has a higher heritability than general major depressive disorder (MDD) yet remains understudied. This study aimed to increase power in PND GWAS and explore its genetic architecture. We meta-analysed an existing study by the Psychiatric Genomics Consortium (PGC) with data from the GLAD+ study and UK Biobank (UKB), yielding 25,452 PND cases and 72,131 controls. Linkage disequilibrium score (LDSC) regression was used to compare genetic correlation profiles of PND and general MDD across traits. Gene, gene-set, and tissue expression analyses were also performed. The genetic correlation between PGC PND and UKB-GLAD+ PND was high (0.93). No genome-wide significant loci emerged from the meta-analysis. The SNP-based heritability of PND on the liability scale was 0.089. PND and MDD displayed broadly similar genetic correlation patterns. Still, PND had a significantly higher genetic correlation with anxiety disorders, while MDD showed higher correlations with cannabis use disorder, bipolar disorder, and ADHD. Tissue expression analysis showed the highest enrichment in brain regions like the cortex and nucleus accumbens. The sample size was not large enough to detect genome-wide significant loci, and further analyses in ancestrally diverse datasets are needed. PND definitions were heterogeneous, and precise information on onset timing across studies was lacking. This study, the largest European ancestry meta-analysis of PND to date, suggests distinct genetic factors may differentiate PND from MDD in general. The findings highlight the need for larger and more ancestrally diverse studies to identify genome-wide significant loci.
Open AccessDisentangling Perinatal Depression from General Major Depression: A GWAS Meta-Analysis and Genetic Correlation Approach in European Datasets
Perinatal depression (PND), defined as depression occurring during the perinatal period, has a higher heritability than general major depressive disorder (MDD) yet remains understudied. This study aimed to increase power in PND GWAS and explore its genetic architecture. We meta-analysed an existing study by the Psychiatric Genomics Consortium (PGC) with data from the GLAD+ study and UK Biobank (UKB), yielding 25,452 PND cases and 72,131 controls. Linkage disequilibrium score (LDSC) regression was used to compare genetic correlation profiles of PND and general MDD across traits. Gene, gene-set, and tissue expression analyses were also performed. The genetic correlation between PGC PND and UKB-GLAD+ PND was high (0.93). No genome-wide significant loci emerged from the meta-analysis. The SNP-based heritability of PND on the liability scale was 0.089. PND and MDD displayed broadly similar genetic correlation patterns. Still, PND had a significantly higher genetic correlation with anxiety disorders, while MDD showed higher correlations with cannabis use disorder, bipolar disorder, and ADHD. Tissue expression analysis showed the highest enrichment in brain regions like the cortex and nucleus accumbens. The sample size was not large enough to detect genome-wide significant loci, and further analyses in ancestrally diverse datasets are needed. PND definitions were heterogeneous, and precise information on onset timing across studies was lacking. This study, the largest European ancestry meta-analysis of PND to date, suggests distinct genetic factors may differentiate PND from MDD in general. The findings highlight the need for larger and more ancestrally diverse studies to identify genome-wide significant loci.
- Open Access
Combined family history and polygenic score prediction of major depressive disorder
Importance: Major depressive disorder (MDD) is a complex psychiatric disorder influenced by genetic, social, and environmental factors. Family history, genome-wide polygenic scores, and childhood trauma are key predictors of MDD onset with distinct contributions. Objective: This study modelled the combined effects of family history of multiple psychiatric disorders, polygenic scores of multiple traits, and childhood trauma, alongside sociodemographic factors on MDD diagnosis and number of episodes. We aimed to build and externally validate predictive models for MDD risk and severity. Participants: We used data from the Genetic Links to Anxiety and Depression Study and other NIHR BioResource studies (GLAD+) and UK Biobank (UKB) collected between 2016 and 2023. Outcomes and measurements: MDD diagnosis followed DSM-5 criteria using online questionnaire data. Family history (Yes/No) was reported for up to 22 psychiatric disorders. Polygenic scores were calculated based on genome-wide association studies (n=22). Participants answered the five-item childhood trauma screener. We used elastic net regression with nested cross-validation to select the best predictors. Results: In GLAD+ (9,927 MDD cases, 4,452 controls), family history explained 17% of the MDD variance, followed by childhood trauma (11%), sociodemographics (10%), and polygenic scores (7%), resulting in 33% of the MDD variance (AUC-ROC=0.84). In UKB (40,667 MDD cases, 70,755 controls), family history explained 13% of the MDD variance, childhood trauma (7%), sociodemographics (6%), and polygenic scores (4%). Combined together, the predictors explained 23% of the variance (AUC-ROC=0.74). The top five individual predictors were family history of depression, childhood trauma, female sex, family history of anxiety, and the MDD polygenic score in both cohorts. The predictive models were externally well-validated across GLAD+ and UKB obtaining comparable predictive performance. Finally, when combined, the predictors explained 26% and 12% of the variance in the number of MDD episodes in GLAD+ and UKB respectively. Conclusions: Integrating family history, PRSs, ChT, and sociodemographic factors can predict risk of an MDD diagnosis and its recurrent course. This model may help identify individuals at high risk for depression in clinical settings, assess its severity, enable early diagnosis and potentially personalize treatment.
Open AccessCombined family history and polygenic score prediction of major depressive disorder
Importance: Major depressive disorder (MDD) is a complex psychiatric disorder influenced by genetic, social, and environmental factors. Family history, genome-wide polygenic scores, and childhood trauma are key predictors of MDD onset with distinct contributions. Objective: This study modelled the combined effects of family history of multiple psychiatric disorders, polygenic scores of multiple traits, and childhood trauma, alongside sociodemographic factors on MDD diagnosis and number of episodes. We aimed to build and externally validate predictive models for MDD risk and severity. Participants: We used data from the Genetic Links to Anxiety and Depression Study and other NIHR BioResource studies (GLAD+) and UK Biobank (UKB) collected between 2016 and 2023. Outcomes and measurements: MDD diagnosis followed DSM-5 criteria using online questionnaire data. Family history (Yes/No) was reported for up to 22 psychiatric disorders. Polygenic scores were calculated based on genome-wide association studies (n=22). Participants answered the five-item childhood trauma screener. We used elastic net regression with nested cross-validation to select the best predictors. Results: In GLAD+ (9,927 MDD cases, 4,452 controls), family history explained 17% of the MDD variance, followed by childhood trauma (11%), sociodemographics (10%), and polygenic scores (7%), resulting in 33% of the MDD variance (AUC-ROC=0.84). In UKB (40,667 MDD cases, 70,755 controls), family history explained 13% of the MDD variance, childhood trauma (7%), sociodemographics (6%), and polygenic scores (4%). Combined together, the predictors explained 23% of the variance (AUC-ROC=0.74). The top five individual predictors were family history of depression, childhood trauma, female sex, family history of anxiety, and the MDD polygenic score in both cohorts. The predictive models were externally well-validated across GLAD+ and UKB obtaining comparable predictive performance. Finally, when combined, the predictors explained 26% and 12% of the variance in the number of MDD episodes in GLAD+ and UKB respectively. Conclusions: Integrating family history, PRSs, ChT, and sociodemographic factors can predict risk of an MDD diagnosis and its recurrent course. This model may help identify individuals at high risk for depression in clinical settings, assess its severity, enable early diagnosis and potentially personalize treatment.
- Open Access
Artificial Intelligence for Pre-Anaemic Iron Deficiency Detection Using Rich Complete Blood Count Data
Iron deficiency (ID) is a major contributor to global disease burden and the leading cause of anaemia. Early detection is important for proactive management, but conventional complete blood count (CBC) screening often fails to identify non-anaemic iron deficiency (NAID) as many individuals maintain haemoglobin and red cell indices within reference ranges. Analysing 153,565 subjects from the INTERVAL, COMPARE and STRIDES studies, we show that CBC screening has only 40.5 % sensitivity for ID detection, falling to 21.9 % for NAID, highlighting a detection gap. CBC analysers generate a wealth of data beyond Electronic Health Record CBC parameters. We demonstrate that artificial intelligence applied to single-cell flow cytometry data from the CBC analyser achieves 83.7 % sensitivity for ID and 79.3 % for NAID. Our findings show that AI can greatly improve detection of a high-prevalence, important condition without changing infrastructure or diagnostic pathways, providing a valuable tool for proactive anaemia management.
Open AccessArtificial Intelligence for Pre-Anaemic Iron Deficiency Detection Using Rich Complete Blood Count Data
Iron deficiency (ID) is a major contributor to global disease burden and the leading cause of anaemia. Early detection is important for proactive management, but conventional complete blood count (CBC) screening often fails to identify non-anaemic iron deficiency (NAID) as many individuals maintain haemoglobin and red cell indices within reference ranges. Analysing 153,565 subjects from the INTERVAL, COMPARE and STRIDES studies, we show that CBC screening has only 40.5 % sensitivity for ID detection, falling to 21.9 % for NAID, highlighting a detection gap. CBC analysers generate a wealth of data beyond Electronic Health Record CBC parameters. We demonstrate that artificial intelligence applied to single-cell flow cytometry data from the CBC analyser achieves 83.7 % sensitivity for ID and 79.3 % for NAID. Our findings show that AI can greatly improve detection of a high-prevalence, important condition without changing infrastructure or diagnostic pathways, providing a valuable tool for proactive anaemia management.
- Open Access
Genome-wide meta-analysis identifies genetic risk factors and implicates multiple body systems in panic attacks and disorder
Introductory paragraph: Panic attacks, sudden episodes of intense fear accompanied by physical and psychological symptoms, affect approximately 23% of the population 1,2 . Panic disorder, diagnosed in 2– 4% 3 , involves recurrent attacks followed by persistent worry about further attacks, leading to functional impairment and avoidance behaviours 1,2 . We conducted genome-wide association meta-analyses of panic attacks and panic disorder (61,746 and 29,775 cases, respectively, and 105,814 controls), identifying the first genome-wide significant variants for both traits (16 for panic attacks; 7 for panic disorder). Geneset analysis using single-cell RNA sequencing data implicated afferent neurons from the eye, heart, and lung in panic attacks, suggesting a critical role for sensory processing and interoceptive awareness. Further analyses suggested that these associations generalize to other psychiatric disorders. These findings offer novel insights into the biological mechanisms underlying panic, the role of afferent neurons, and may inform the development of more targeted and effective interventions.
Open AccessGenome-wide meta-analysis identifies genetic risk factors and implicates multiple body systems in panic attacks and disorder
Introductory paragraph: Panic attacks, sudden episodes of intense fear accompanied by physical and psychological symptoms, affect approximately 23% of the population 1,2 . Panic disorder, diagnosed in 2– 4% 3 , involves recurrent attacks followed by persistent worry about further attacks, leading to functional impairment and avoidance behaviours 1,2 . We conducted genome-wide association meta-analyses of panic attacks and panic disorder (61,746 and 29,775 cases, respectively, and 105,814 controls), identifying the first genome-wide significant variants for both traits (16 for panic attacks; 7 for panic disorder). Geneset analysis using single-cell RNA sequencing data implicated afferent neurons from the eye, heart, and lung in panic attacks, suggesting a critical role for sensory processing and interoceptive awareness. Further analyses suggested that these associations generalize to other psychiatric disorders. These findings offer novel insights into the biological mechanisms underlying panic, the role of afferent neurons, and may inform the development of more targeted and effective interventions.
- Open Access
- 11 June 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1511-1524
Array Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and HNA, respectively) to support selection of blood products matched beyond ABO/Rh. Typing samples from 6946 donors of European, African, Admixed American, South Asian, and East Asian ancestry at two different laboratories showed a genotype reproducibility of ≥99% for 17 244 variants, translating to 99.98%, 99.90%, and 99.93% concordance across 338 372 HEA, 53 270 HPA, and 107 094 HLA genotypes, respectively. Compared to previous clinical typing data, concordance was 99.9% and 99.6% for 245 874 HEA and 3726 HPA comparisons, respectively. HLA types were 99.1% concordant with clinical typing across 8130 comparisons, with imputation accuracy higher in Europeans versus non-Europeans. Seven variant RHD alleles, a GYPB deletion underlying the U− phenotype, and 14 high-frequency antigen negative types were also detected. Beyond blood typing, hereditary hemochromatosis-associated HFE variants were identified in 276 donors. We found that the UBDT_PC1 array can reliably type a wide range of blood cell antigens across diverse ancestries. Reproducibility and accuracy were retained when transfusion-relevant targets from the UBDT_PC1 array were incorporated into the UKBB_v2.2 genome-wide typing array. The results represent the potential for significant advancement towards improved patient care by reducing harm in transfused patients through extended matching.
- 11 June 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1511-1524
Open AccessArray Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and HNA, respectively) to support selection of blood products matched beyond ABO/Rh. Typing samples from 6946 donors of European, African, Admixed American, South Asian, and East Asian ancestry at two different laboratories showed a genotype reproducibility of ≥99% for 17 244 variants, translating to 99.98%, 99.90%, and 99.93% concordance across 338 372 HEA, 53 270 HPA, and 107 094 HLA genotypes, respectively. Compared to previous clinical typing data, concordance was 99.9% and 99.6% for 245 874 HEA and 3726 HPA comparisons, respectively. HLA types were 99.1% concordant with clinical typing across 8130 comparisons, with imputation accuracy higher in Europeans versus non-Europeans. Seven variant RHD alleles, a GYPB deletion underlying the U− phenotype, and 14 high-frequency antigen negative types were also detected. Beyond blood typing, hereditary hemochromatosis-associated HFE variants were identified in 276 donors. We found that the UBDT_PC1 array can reliably type a wide range of blood cell antigens across diverse ancestries. Reproducibility and accuracy were retained when transfusion-relevant targets from the UBDT_PC1 array were incorporated into the UKBB_v2.2 genome-wide typing array. The results represent the potential for significant advancement towards improved patient care by reducing harm in transfused patients through extended matching.
- Open Access
Array Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and HNA, respectively) to support selection of blood products matched beyond ABO/Rh. Typing samples from 6946 donors of European, African, Admixed American, South Asian, and East Asian ancestry at two different laboratories showed a genotype reproducibility of ≥99% for 17 244 variants, translating to 99.98%, 99.90%, and 99.93% concordance across 338 372 HEA, 53 270 HPA, and 107 094 HLA genotypes, respectively. Compared to previous clinical typing data, concordance was 99.9% and 99.6% for 245 874 HEA and 3726 HPA comparisons, respectively. HLA types were 99.1% concordant with clinical typing across 8130 comparisons, with imputation accuracy higher in Europeans versus non-Europeans. Seven variant RHD alleles, a GYPB deletion underlying the U− phenotype, and 14 high-frequency antigen negative types were also detected. Beyond blood typing, hereditary hemochromatosis-associated HFE variants were identified in 276 donors. We found that the UBDT_PC1 array can reliably type a wide range of blood cell antigens across diverse ancestries. Reproducibility and accuracy were retained when transfusion-relevant targets from the UBDT_PC1 array were incorporated into the UKBB_v2.2 genome-wide typing array. The results represent the potential for significant advancement towards improved patient care by reducing harm in transfused patients through extended matching.
Open AccessArray Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and HNA, respectively) to support selection of blood products matched beyond ABO/Rh. Typing samples from 6946 donors of European, African, Admixed American, South Asian, and East Asian ancestry at two different laboratories showed a genotype reproducibility of ≥99% for 17 244 variants, translating to 99.98%, 99.90%, and 99.93% concordance across 338 372 HEA, 53 270 HPA, and 107 094 HLA genotypes, respectively. Compared to previous clinical typing data, concordance was 99.9% and 99.6% for 245 874 HEA and 3726 HPA comparisons, respectively. HLA types were 99.1% concordant with clinical typing across 8130 comparisons, with imputation accuracy higher in Europeans versus non-Europeans. Seven variant RHD alleles, a GYPB deletion underlying the U− phenotype, and 14 high-frequency antigen negative types were also detected. Beyond blood typing, hereditary hemochromatosis-associated HFE variants were identified in 276 donors. We found that the UBDT_PC1 array can reliably type a wide range of blood cell antigens across diverse ancestries. Reproducibility and accuracy were retained when transfusion-relevant targets from the UBDT_PC1 array were incorporated into the UKBB_v2.2 genome-wide typing array. The results represent the potential for significant advancement towards improved patient care by reducing harm in transfused patients through extended matching.
- Open Access
- 23 September 2024
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 245-257
Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction
The spectrum, pathophysiology and recovery trajectory of persistent post-COVID-19 cognitive deficits are unknown, limiting our ability to develop prevention and treatment strategies. We report the 1-year cognitive, serum biomarker and neuroimaging findings from a prospective, national study of cognition in 351 COVID-19 patients who required hospitalization, compared with 2,927 normative matched controls. Cognitive deficits were global, associated with elevated brain injury markers and reduced anterior cingulate cortex volume 1 year after COVID-19. Severity of the initial infective insult, postacute psychiatric symptoms and a history of encephalopathy were associated with the greatest deficits. There was strong concordance between subjective and objective cognitive deficits. Longitudinal follow-up in 106 patients demonstrated a trend toward recovery. Together, these findings support the hypothesis that brain injury in moderate to severe COVID-19 may be immune-mediated, and should guide the development of therapeutic strategies.
- 23 September 2024
- Published by Springer Nature in Nature Medicine
- Vol. 31 (1) , 245-257
Open AccessPosthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction
The spectrum, pathophysiology and recovery trajectory of persistent post-COVID-19 cognitive deficits are unknown, limiting our ability to develop prevention and treatment strategies. We report the 1-year cognitive, serum biomarker and neuroimaging findings from a prospective, national study of cognition in 351 COVID-19 patients who required hospitalization, compared with 2,927 normative matched controls. Cognitive deficits were global, associated with elevated brain injury markers and reduced anterior cingulate cortex volume 1 year after COVID-19. Severity of the initial infective insult, postacute psychiatric symptoms and a history of encephalopathy were associated with the greatest deficits. There was strong concordance between subjective and objective cognitive deficits. Longitudinal follow-up in 106 patients demonstrated a trend toward recovery. Together, these findings support the hypothesis that brain injury in moderate to severe COVID-19 may be immune-mediated, and should guide the development of therapeutic strategies.